Navigation Links
Smac-ing lung cancer to death
Date:11/12/2007

Howard Hughes Medical Institute researchers have developed a small molecule that can turn the survival signal for a variety of cancer cells into a death signal. The molecule mimics the activity of Smac, a protein that triggers the suicide of some types of cancer cells.

The researchers say their findings suggest that Smac-mimetic compounds could be useful as targeted cancer treatments for lung and other cancers. Such therapy may be less toxic to healthy cells than current compounds used in cancer chemotherapy.

The researchers, led by Howard Hughes Medical Institute investigator Xiaodong Wang, published their findings in the November, 2007, issue of the journal Cancer Cell. Wang is at the University of Texas Southwestern Medical Center.

Cells that are defective or that become unnecessary during growth and development are induced to commit suicide through a finely balanced process known as apoptosis, or programmed cell death. A protein called Smac, which is a shortened version of second mitochondria-derived activator of apoptosis, is a part of the cells programmed cell death machinery. When that machinery is switched on, Smac is released from the mitochondria and triggers the pathway that kills damaged or abnormal cells. Cancer cells, however, can survive Smacs death signal by switching off the apoptotic machinery.

To see if they could get around this problem, Wang and other researchers have developed small-molecule mimetics of Smac that can enter the cell and trigger apoptosis. These mimetic molecules do their damage without the need for the Smac signal from the mitochondria. In earlier studies, Wang and his colleagues found that a Smac mimetic that they developed in the lab could kill cancer cells in culture. But they found that the cancer cells are only killed when the mimetic molecule is introduced in conjunction with another component of the apoptotic machinery known as TNF.

In the new studies published in Cancer Cell, Wang and his colleagues found that a significant percentage of human non-small-cell lung cancer cell lines were sensitive to treatment by the Smac mimetic alone. When the researchers introduced those sensitive cells into mice and allowed them to produce tumors, they found that the Smac mimetic caused the tumors to regress and, in some cases, even disappear.

These findings made us wonder what it was about these cell lines that made them sensitive to the Smac mimetic alone, said Wang. Cancer cells are hard to kill, but these cell lines seemed to have already become sensitized to apoptosis.

The researchers studies revealed that the sensitive cell lines produced their own TNF, so they were already primed for apoptosis. The paradox, said Wang, is that TNF signaling is also part of a complex pathway that gives cancer cells a survival signal, offering them a growth advantage. The researchers also found that some breast cancer and melanoma cell lines were sensitive to the Smac mimetic alone.

Thus, in these cancer cell lines, the TNF survival advantage turns out to be a fatal flaw, because the same pathway can be switched to apoptosis by Smac mimetics, said Wang. So, for some cancers, we might be able to use Smac mimetics as a single treatment agent. And we can use the presence of TNF as a marker to tell us which tumors will respond to the Smac mimetic alone.

People have been suspecting for a long time that some cancer cells may somehow turn on their apoptotic pathway already, said Wang. And now we know what pathway they turn on and why. We can take advantage of this phenomenon for potential cancer therapy by switching a signal into a deadly one with Smac mimetics.


'/>"/>

Contact: Jennifer Michalowski
michalow@hhmi.org
301-215-8576
Howard Hughes Medical Institute
Source:Eurekalert

Related medicine news :

1. Conventional prognostic factors fail to explain better prostate cancer survival in most Asian men
2. Survival differences by race most apparent in advanced stages of breast cancer
3. MRI finds breast cancer before it becomes dangerous
4. Investigators uncover intriguing clues to why persistent acid reflux sometimes turns into cancer
5. Pathway links inflammation, angiogenesis and breast cancer
6. Radiologists encouraged to look beyond cancer for clinically unseen diseases
7. Diet high in meat, fat and refined grains linked to risk for colon cancer recurrence, death
8. Immune deficiency linked to a type of eye cancer
9. Drop in breast cancer incidence linked to hormone use, not mammograms
10. Breast cancer prevention practices vary across Canada
11. First biomarker discovered that predicts prostate cancer outcome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2017)... ... 30, 2017 , ... AudioEducator, a leader in training conferences ... Through Discharge Planning ” with noted expert Sue Dill Calloway, RN, MSN, JD., ... to prevent readmissions in light of the most recent programs at the Centers ...
(Date:3/29/2017)... ... March 29, 2017 , ... ARI Network Services, Inc. (NASDAQ: ARIS) announced ... dealer websites for its network of more than 650 U.S.-based dealers. Rhino, a member ... including rotary and flail mowers and cutters, rear blades, post hole diggers, pasture renovators, ...
(Date:3/29/2017)... ... ... Full Contact K9, an Atlanta-based dog services provider, has recently teamed up ... owners in creating legally-enforceable pet trusts for their canine companions. , Therilus, a ... their new companion. Says Evan Dunbar, CEO of Full Contact K9, “When our clients ...
(Date:3/29/2017)... ... , ... Youth Futures International (YFI) premiered its Serve, Learn, & Empower program ... students who have participated in the program every summer. The 2017 Serve, Learn, ... for enrollment. Visit http://www.ghana.yfiexperience.org to learn more. , “I have sent ...
(Date:3/29/2017)... Florida (PRWEB) , ... March 29, 2017 , ... ... be hosting several educational opportunities for attending prescribers at the upcoming World Congress, ... Network said, “A4M has always been recognized as the visionary leader in the ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... Calif. , Mar 29, 2017  Providence ... technology, announced the addition of two industry veterans ... has joined the company to lead Global ... International leadership.  Together, Mr. Lynch and Mr. Scott ... Mr. Lynch joins the company ...
(Date:3/29/2017)... N.J. , March 29, 2017  Glenmark ... results for GSP 301, an investigational fixed-dose combination ... (665 mcg) administered twice-daily as a nasal spray ... rhinitis. These results are from a recently completed ... of GSP 301 combination therapy versus mometasone, olopatadine ...
(Date:3/29/2017)... , March 29, 2017  The Pharmaceutical Care Management ... new PhRMA report on patient out-of-pocket spending: ... and Medicaid Services (CMS), the average amount spent out-of-pocket ... of drug spending in 2016, down from 23% in ... pricing problem, not a coverage problem. Health plans don,t ...
Breaking Medicine Technology: